Business Wire

Brest University Hospital and HEMARINA Present Positive New Advances from the Initial Clinical Trial of HEMO2life® at the American Transplant Congress in Seattle

Jaa

Brest University Hospital and HEMARINA announced at a poster 1 session at the American Transplant Congress ( American Transplant Congress  "ATC") 2 , the leading global organ transplant congress, the interim 3-month results from the OxyOp 3 study, presented by Professor Yannick Le Meur, the trial's principal investigator. This study, conducted at six French transplant centres, followed, for one year, patients who had received a kidney that had been preserved in a solution containing the HEMO 2 life ® additive.

Brest University Hospital and HEMARINA had already published initial very positive results on the safety in use of HEMO2life® in November 2017 (click here for more details), namely:

  • No product-related graft loss, according to the Independent Data Safety Monitoring Board (IDSMB),
  • No death at 3 months,
  • No major adverse event related to HEMO2life®,
  • No immunological, allergic or pro-thrombotic effects,
  • Promising preliminary efficacy data.

The new results presented confirm this major medical innovation in kidney transplants. In terms of efficacy, two major results should be noted:

  • Fewer patients who received a kidney preserved with HEMO2life® suffered from Delayed Graft Function (DGF): 6.98% vs 26.19%. This marker, the DGF, is predictive of the long-term success of the transplant,
  • Another blood parameter, like serum creatinine, which indicates a defect in the elimination of organ waste in the blood, also marked the difference between the two patient groups; patients whose kidneys had been preserved with HEMO2life® reached target levels of serum creatinine in an average of 7 days, compared with an average of 13 days in the other patient group. Moreover, this parameter is usually studied to assess the success of a kidney transplant.

Professor Yannick Le Meur, Nephrologist, University Professor, Head of Department at Brest University Hospital, stated "HEMARINA's technology is extremely promising: its use by the surgical teams is simple and can easily be integrated into current practices. It should make the teams' work easier by giving them more time to prepare transplants. I am therefore very pleased to present the results of this world first to the entire scientific community gathered at the ATC and to be able to share them with colleagues worldwide".

Dr Franck Zal, co-founder and CEO of HEMARINA added: "We are delighted with the results obtained. HEMO 2 life ® enables delayed graft function to be reduced by almost two-thirds. This criterion is a predictor of the long-term survival of the transplant and unambiguously demonstrates excellent preservation of the graft compared with existing clinical techniques. We are fully committed to bringing this medical device onto the market. We expect HEMO 2 life ® to very rapidly become the benchmark in graft preservation. These clinical results contribute to strengthening our technological platform. A transplant is so precious that we should give it every chance of success. We owe it to the donors, the receivers, and their respective families".

1 Poster: reference D48 presented on Tuesday 5 June 18:00 – 19:00, Hall 4 EF
2 ATC: global congress for Health professionals who are interested in the clinical and research aspects of organ transplantation. It brings together 5,000 participants and exhibitors
3 OxyOp: evaluation of a marine OXYgen carrier, HEMO2life®, for hypOthermic kidney graft preservation before transplantation (first human clinical study of a marine oxygen carrier).

References:

Congress website: https://atcmeeting.org/
Programme: https://atcmeeting.org/sites/default/files/docs/2018/atc2018_cti_program_4-30-18.pdf

Further information on the OxyOp trial can be found at https://www.clinicaltrials.gov./

For more information, visit our website: www.hemarina.com

Contact information

Actifin
Jenna Driff, Tel: +33-(0)1-56-88-11-21
E-mail: jdriff@actifin.fr

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 17:00Tiedote

Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With

Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 16:41Tiedote

Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel

Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 15:00Tiedote

Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i

Announcement by Viking Corp on Tecnotree22.6.2018 14:09Tiedote

In the interests of stakeholder transparency, this announcement provides background and context to Viking's file bankruptcy proceedings upon Tecnotree: As many of you will now know, Viking Corp was recently forced to file bankruptcy proceedings upon Tecnotree, which were withdrawn on the 19 June. In the interests of stakeholder transparency, we make this Announcement to provide background and context to this action. Firstly, we would reflect on the recent history of our attempts to partner with Tecnotree and all its stakeholders. Viking launched a Tender Offer (TO), having conducted detailed discussions with the Tecnotree Board and our advisors. On the basis of those discussions, we were very confident that the TO price of 10 cents per share provided truly superior value for shareholders. So did the Tecnotree Board as evidenced by their unanimous recommendation of our Offer and of course, further evidenced by the current prevailing market price. This TO was supported in the most vigoro

HeartSciences Named “Start-Up to Watch”22.6.2018 14:00Tiedote

HeartSciences is delighted to have been highlighted as “Start-Up to Watch” in the June 8, 2018 issue of the MedTech Strategist. The article titled “HEARTSCIENCES: ARTIFICIAL INTELLIGENCE IMPROVES FRONTLINE RISK STRATIFICATION FOR HEART DISEASES” discusses HeartSciences’ role in addressing the current challenges and significant unmet need to identify heart disease at an early stage and reduce the high prevalence of expensive diagnostic testing with low yields. The article highlights the enormous opportunity for HeartSciences’ breakthrough MyoVista® Wavelet ECG (wavECG™) technology to benefit patients and to reduce health system costs and references a recently published study titled “Prediction of Abnormal Myocardial Relaxation From Signal Processed Surface ECG” in the Journal of American College of Cardiology (JACC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005088/en/ MyoVista Wavelet ECG Cardiac Testing Device (P

High-Performance Solutions and Complete Protection for Critical Installations: the Latest Innovations from CNIM and Its Bertin Subsidiary to Be Unveiled at WNE 201822.6.2018 12:39Tiedote

The third edition of the World Nuclear Exhibition – major event for the global nuclear energy community – will be held at Paris-Villepinte, June 26 th to 28 th , 2018. CNIM and Bertin Technologies , leading players in the fields of nuclear equipment, safe handling and instrumentation for the complete protection of nuclear power plants, will be unveiling their joint offerings at this exhibition (booth D125-Hall 7). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005185/en/ CNIM's high safety fuel handling systems (Photo: Business Wire) Based on its long experience of major nuclear projects and its cutting-edge industrial capabilities, CNIM’s offering reflects its ability to innovate and adapt to the most difficult environments. Highlights on its exhibition booth will include: The design and manufacturing of high-safety fuel handling systems (notably the design of three remotely operated spent fuel handling and transferri

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme